Dr. Leeds joined Novartis in 2003 where she co-invented and co-led the project team for the novel antibacterial LFF571 through Ph2 and became Head of Antibacterial Discovery in 2010. In 2018, Jennifer joined Novartis BD&L. Jennifer is responsible for identifying new technology from organizations in the western US and across Canada, across all therapeutic areas, for potential partnering with Novartis. Jennifer also supports NIBR Translational Medicine and Oncology, globally, and has led many NIBR out-licensing projects. Jennifer is a Board Observer for Bluejay Therapeutics and was a BO for Caribou Bio prior to their IPO. Jennifer is also a Director on the
Cornell University CALS Alumni Association Board and was previously an Independent Director on the Board of 1910 Genetics. Jennifer serves on the Novo Holdings REPAIR Impact Fund SSB, is an Expert Reviewer for Innosuisse, and a member of imYEG Council of Founders. Jennifer received her BSc in Microbiology from Cornell University in 1991, her PhD in Medical Microbiology and Immunology from the University of Wisconsin-Madison, and did her postdoc at Harvard Medical School in Microbiology and Molecular Genetics.
Cornell University CALS Alumni Association Board and was previously an Independent Director on the Board of 1910 Genetics. Jennifer serves on the Novo Holdings REPAIR Impact Fund SSB, is an Expert Reviewer for Innosuisse, and a member of imYEG Council of Founders. Jennifer received her BSc in Microbiology from Cornell University in 1991, her PhD in Medical Microbiology and Immunology from the University of Wisconsin-Madison, and did her postdoc at Harvard Medical School in Microbiology and Molecular Genetics.
Speaking In
3:00 PM - 4:00 PM
Tuesday, June 6
